04-07-2025
Shilpa Medicare subsidiary clears GMP inspection from ANVISA with no major observations
By Aman Shukla Published on July 4, 2025, 16:10 IST
Shilpa Medicare Limited announced that its wholly owned subsidiary, Shilpa Pharma Lifesciences Limited (Unit-1), has successfully completed a Good Manufacturing Practice (GMP) inspection conducted by the Brazilian regulatory authority, ANVISA.
In the exchange filing, the company shared, 'This is to inform you that the Shilpa Medicare Limited's 100% subsidiary, Shilpa Pharma Lifesciences Limited, Unit-1 has successfully completed GMP inspection from Brazilian regulatory authority, ANVISA. '
The inspection took place from June 30 to July 4, 2025, and concluded with no critical or major observations—a key milestone for the company's global regulatory compliance. Only minor procedural observations and recommendations were noted, which were discussed during the course of the audit.
Shilpa Medicare stated that it remains committed to maintaining the highest quality and regulatory standards. The company will submit a Corrective and Preventive Action (CAPA) plan to address the minor points raised, within the stipulated timelines set by the agency.
This successful outcome reinforces Shilpa's position in regulated markets and supports its ongoing efforts to expand its international presence, particularly in Latin America.
Ahmedabad Plane Crash
Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
